- Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock
- Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update
- Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
- Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma
- Allogene Therapeutics Announces Q2 Investor Conference Participation
- Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
- Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease
- Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
- Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference
- Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia
More ▼
Key statistics
On Friday, Allogene Therapeutics Inc (ALLO:NSQ) closed at 2.77, 24.22% above the 52 week low of 2.23 set on Dec 01, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.00 |
---|---|
High | 3.01 |
Low | 2.77 |
Bid | 2.77 |
Offer | 2.78 |
Previous close | 3.01 |
Average volume | 2.43m |
---|---|
Shares outstanding | 208.38m |
Free float | 154.12m |
P/E (TTM) | -- |
Market cap | 577.22m USD |
EPS (TTM) | -1.78 USD |
Data delayed at least 15 minutes, as of May 17 2024 21:00 BST.
More ▼